Just24 Aug 2017 12:32
Put down the phone after a long detailed conversation with CCI CEO Mike Hayball, He was very cautious on his outlook and was very upbeat on the new China distribution deal and the significance of that
CE still on course for "soon " that subject was tighter than a ducks backside , There main priority is launching a clinical product on the market and he was at pains to point out the unique properties and attributes that there software system holds not least the smooth integration into current hospital systems ( hopefully a fuller explanation & breakdown will be forthcoming on that subject ) + the per patient per scan charges levied for TexRAD lung and without being abrupt there are untold patients that will benefit from TexRad,s ability to categorize specific patient care depending on the diagnosis , Which of course should apply to future further applications in Liver ,Brain ,Breast , colon etc etc
My ball park figures on TexRAD Lung based on 30,000 lung cancer patients per year having just the 1 scan is UK £1.5 million and Europe x 10 of that say £15 million a year , Rest of the world ??? Well work it out yourselves ,,,The market size is USA - lungcancer.about.com Obviously this is just Lung so we can elaborate on those figures for other applications , These are MY ( Market Size of the Prize ) figures not quoted from any source
Alianz ! Your thoughts on the Research to Commercial are conservative Amigo
Rome was not built overnight so this has to be allowed to grow and patience needed whilst the team is expanded to handle the increase in volume expected going into 2018 as right now they are pushed to cope with current demands
MH comes across as a genuine conscientious Geezer who is very passionate about the work he does to make patients life more comfortable in there unfortunate predicament and praised Balaji Ganeshan for his qualities in getting out in the field to promote TexRAD in his role as Director of new business @ Feedback and stated his contacts are very influential
SO ! In summary -
All still on course for CE" soon" but MH was at pains to stress CE ( just a miniscule part of the equation ) was not the B and end all, It was the progression to introduce a Clinical Product to the market that will ultimately bring home the Bacon and keep us all happy as LTH